135 related articles for article (PubMed ID: 10961603)
1. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates.
Tremblay C; Merrill DP; Chou TC; Hirsch MS
J Acquir Immune Defic Syndr; 1999 Dec; 22(5):430-6. PubMed ID: 10961603
[TBL] [Abstract][Full Text] [Related]
2. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
Morse GD; Rosenkranz S; Para MF; Segal Y; Difrancesco R; Adams E; Brizz B; Yarasheski KE; Reichman RC
Antimicrob Agents Chemother; 2005 Aug; 49(8):3373-81. PubMed ID: 16048950
[TBL] [Abstract][Full Text] [Related]
3. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
4. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
5. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro.
Merrill DP; Manion DJ; Chou TC; Hirsch MS
J Infect Dis; 1997 Jul; 176(1):265-8. PubMed ID: 9207379
[TBL] [Abstract][Full Text] [Related]
6. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.
Chaillou S; Durant J; Garraffo R; Georgenthum E; Roptin C; Clevenbergh P; Dunais B; Mondain V; Roger PM; Dellamonica P
HIV Clin Trials; 2002; 3(6):493-501. PubMed ID: 12501133
[TBL] [Abstract][Full Text] [Related]
7. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
Easterbrook PJ; Newson R; Ives N; Pereira S; Moyle G; Gazzard BG
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):350-64. PubMed ID: 11468423
[TBL] [Abstract][Full Text] [Related]
8. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease inhibitors. A review for clinicians.
Deeks SG; Smith M; Holodniy M; Kahn JO
JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
[TBL] [Abstract][Full Text] [Related]
10. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.
Race E; Dam E; Obry V; Paulous S; Clavel F
AIDS; 1999 Oct; 13(15):2061-8. PubMed ID: 10546858
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
14. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
Chi J; Jayewardene AL; Stone JA; Motoya T; Aweeka FT
J Pharm Biomed Anal; 2002 Oct; 30(3):675-84. PubMed ID: 12367693
[TBL] [Abstract][Full Text] [Related]
16. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
Chai H; Yang H; Yan S; Li M; Lin PH; Lumsden AB; Yao Q; Chen C
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):12-9. PubMed ID: 16123675
[TBL] [Abstract][Full Text] [Related]
17. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
Jarvis B; Faulds D
Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
[TBL] [Abstract][Full Text] [Related]
18. The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.
Karmochkine M; Si Mohamed A; Piketty C; Ginsburg C; Raguin G; Schneider-Fauveau V; Gutmann L; Kazatchkine MD; Belec L
Antiviral Res; 2000 Sep; 47(3):179-88. PubMed ID: 10974370
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
Hoffmann F; Notheis G; Wintergerst U; Eberle J; Gürtler L; Belohradsky BH
Pediatr Infect Dis J; 2000 Jan; 19(1):47-51. PubMed ID: 10643850
[TBL] [Abstract][Full Text] [Related]
20. A review of dual protease inhibitor therapy.
Gallant JE
Hopkins HIV Rep; 1998 May; 10(3):1, 4-5. PubMed ID: 11365490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]